Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company") (TSX
VENTURE:IMV), a clinical stage vaccine and immunotherapy company, today
announced that pursuant to terms and conditions of the Company's stock option
plan, it has granted 1,731,500 stock options to employees, consultants, officers
and directors. Employees and consultants were granted an aggregate of 457,500
options and officers and directors were granted an aggregate of 1,274,000
options. The options were granted on January 17, 2014 at an exercise price of
$0.74. The options for the employees, consultants and directors will vest in
three equal tranches at 6, 12, and 18 months from date of grant and the options
for the officers will vest in three equal tranches, the first on the date of
grant and the others on the first and second anniversary of the date of grant.
All options are set to expire five years from the date of grant.


Immunovaccine expects three trials to be initiated in 2014 with its cancer
immunotherapies, the largest of which is a randomized Phase II trial of
DPX-Survivac in ovarian cancer being sponsored and conducted by Canada's NCIC
Clinical Trials Group (NCIC CTG). The trial is expected to begin enrolling the
first of its 250 patients in 2014. Additionally, researchers at the University
of Rome have announced plans to initiate a Phase II trial of DPX-Survivac in
glioblastoma (brain cancer) patients in the first half of 2014. A third trial,
using DPX-0907 to treat breast and ovarian cancer, is planned for initiation at
Busto Arsizio Hospital in Milan.


About Ovarian Cancer

Ovarian cancer accounts for more deaths than any other gynecologic cancer.
Symptoms do not occur until it is in the later stages of the disease, reducing
the chance for successful treatment and remission. It kills more than 100,000
women annually around the world. Improved surgical techniques have helped to
reduce the rate of recurrence according to some studies, but the average life
expectancy of newly diagnosed ovarian cancer patients is less than four years. 


About Glioblastoma

Glioblastoma, the most common form of brain cancer, is a fast-growing tumor type
that develops from astrocytes, a type of glial cell present in the brain. The
National Cancer Institute estimates that more than 23,000 Americans will be
diagnosed with brain and other nervous system tumors in 2014. Glioblastoma
accounts for approximately 15 percent of all brain tumors. The current standard
of care for glioblastoma patients calls for patients to receive maximum surgical
resection combined with radiation and concomitant and adjuvant temozolomide
therapy. Newly diagnosed glioblastoma patients have a median overall survival of
less than 24 months.


About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease
vaccines based on the Company's DepoVax(TM) platform, a patented formulation
that provides controlled and prolonged exposure of antigens and adjuvant to the
immune system. Immunovaccine has advanced two T cell activation therapies for
cancer through Phase I human clinical trials. Lead cancer vaccine therapy,
DPX-Survivac, is expected to enter Phase II clinical studies in both ovarian
cancer and glioblastoma (brain cancer). The Company is also advancing an
infectious disease pipeline including innovative vaccines for respiratory
syncytial virus (RSV) and anthrax.  


Connect at www.imvaccine.com

This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future, including information regarding the use of
proceeds of the financing, is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release except
as required by law. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine, Inc.
Dr. Marc Mansour
Chief Operating Officer
(902) 492-1819
mmansour@imvaccine.com
www.imvaccine.com


Vida Strategic Partners (media)
Tim Brons
(415) 675-7402
tbrons@vidasp.com